(Q58097652)

English

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

article

In more languages

Statements

scholarly article

0 references

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response (English)

0 references

0 references

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

object named as

Ye Oo

13

0 references

object named as

Bettina E. Hansen

16

0 references

object named as

Thomas Berg

15

0 references

Pierre-François Pradat

12

object named as

Pierre Pradat

0 references

Heiner Wedemeyer

17

object named as

Heiner Wedemeyer

0 references

9

object named as

Maria Buti

0 references

Florian van Bömmel

11

object named as

Florian van Bömmel

0 references

author name string

Roeland Zoutendijk

1

0 references

Jurriën G. P. Reijnders

2

0 references

Ashley Brown

3

0 references

Fabien Zoulim

4

0 references

David Mutimer

5

0 references

Katja Deterding

6

0 references

Jörg Petersen

7

0 references

Wolf Peter Hofmann

8

0 references

Teresa Santantonio

10

0 references

Marc Luetgehetmann

14

0 references

Harry L. A. Janssen

18

0 references

language of work or name

0 references

publication date

25 July 2011

0 references

0 references

54

0 references

2

0 references

443-451

0 references

Benefits and risks of nucleoside analog therapy for hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Side effects of long-term oral antiviral therapy for hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24406

21 January 2018

Identifiers

10.1002/HEP.24406

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58097652&oldid=2039581448"